MedCrypt Announces $5.3 M Series A Funding Round

SAN DIEGO, May 7, 2019 /PRNewswire/ — MedCrypt, a leading medical device cybersecurity software provider, today announced a $5.3 million Series A funding round led by Section 32, with participation from Eniac Ventures and Y Combinator. MedCrypt was part of Y Combinator’s Winter 2019 batch.

“Last October, the FDA released a major update to its premarket cybersecurity guidance for medical devices, publishing guidelines that line up just about perfectly with the solution we began developing three years ago,” said MedCrypt founder and CEO, Mike Kijewski. “Internet-connected medical technology is entering the market at light speed, calling for devices to be secure by design, which leads to a heightened level of patient safety at all times. We’re thrilled to see continued support from various groups in the industry, from the government to healthcare institutions and device vendors, along with support from our partners to help us further develop our technology and expand our team.”

The HIPAA Security Rule has been in effect for 14 years, aiming to protect electronic health data, yet a new study from CynergisTek reports the healthcare industry has only managed to achieve 72% compliance with it, leaving a gap that poses a security risk for those who are not yet compliant. The study also reports healthcare is expected to suffer 2-3 times more cyberattacks in 2019 than other industries. This data makes patient safety a critical area of focus.

“Patient data privacy has long been a concern, but the healthcare industry is just beginning to address patient safety risks presented by internet-connected healthcare technology,” said Vidya Murthy, vice president of operations, MedCrypt. “Research shows a 13.3% higher mortality rate for patients experiencing a cardiac arrest whose care was delayed by four minutes. While cybersecurity attacks to a device such as a pacemaker seem more dangerous, delays to patient care due to cyberattacks are much more real and likely.”

MedCrypt will use the funds to expand its team, adding new members in sales and engineering roles, and further develop its technology. MedCrypt’s security software allows device vendors to use cryptography to secure data traveling between or stored on devices. MedCrypt then provides remote, real-time monitoring to alert medical device vendors of suspicious behavior that may yield potential security threats to their company, devices and patients.

This round brings MedCrypt’s total funds raised to $8.4 million.

About MedCrypt

MedCrypt gives medical device vendors access to cybersecurity features in a few lines of code. The U.S. Food & Drug Administration (FDA) published an updated Premarket Cybersecurity Guidance for medical devices in October of 2018, which sets guidelines that are in line with the solution MedCrypt developed in 2016. MedCrypt was part of the Winter 2019 Y Combinator batch and is based in San Diego, Calif.

For more information, visit www.medcrypt.com.

Contact: Brenda Manea
BAM Communications
brenda@bamcommunications.biz

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/medcrypt-announces-5-3-m-series-a-funding-round-300845564.html

SOURCE MedCrypt

Staff

Recent Posts

Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes

Company Awards $1.8M in Grants to Eight Organizations in Brazil, India, Thailand and the United…

49 mins ago

Universal Recall Platform Alliance Launches to Keep Patients Safe

Industry initiative URPA broadens calls to improve speed, accuracy of recall communicationWEST HOLLYWOOD, CA /…

49 mins ago

Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates

ELI-002 2P clinical immunogenicity data were accepted for a poster presentation at the AACR Annual…

4 hours ago

Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update

AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or…

4 hours ago

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

-- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by…

4 hours ago

Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update

NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading…

4 hours ago